Mary’s Medicinals Receives Notice of Allowance of US Patent For Transdermal Cannabinoid Formulations
Colorado Company to Receive Pioneering Patent Covering Transdermal Formulations of Cannabis
DENVER, May 12, 2016 /PRNewswire/ — Mary’s Medicinals, developer of award-winning cannabis products including the first transdermal cannabis patch, announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) on May 10, 2016 for its innovative transdermal cannabinoid gel technology.
We are pleased that the Patent and Trademark Office has approved our application. The PTO has only granted an extremely limited number of cannabis-related patents – almost exclusively to major international pharmaceutical corporations, research institutions and the Federal Government.
Nicole Smith, founder & CEO, Mary’s Medicinals
As a small startup company, securing this protection for our intellectual property and the recognition of the uniqueness of our offerings will bolster our continued leadership in this rapidly growing industry.
Mary’s Transdermal Cannabinoid Gel Pen provides an easy, accurate and discreet way to consume medical cannabis. Mary’s Medicinals currently offers THC Indica, THC Sativa, CBN and CBD formulations of the infused transdermal gel. Additionally, Mary’s sister company – Mary’s Nutritionals – manufactures a CBD Transdermal Gel Pen that is available to customers nationwide through marysnutritionals.com. Mary’s Nutritionals also offers a formulation of its Gel Pen designed specifically for Pets, and another version made with Charlotte’s Web™ Hemp Oil.
Mary’s Medicinals established itself as one of the most trusted and innovative producers of canna-based products in Coloradoand has since expanded to Washington, California, Oregon, Vermont and Arizona – with launches in additional states planned throughout 2016 and 2017. Mary’s was first to offer THCa and CBN products; discovered harvesting techniques for the isolation of CBC, and continues to develop cutting edge approaches for isolating, manufacturing and delivering medicinal cannabis.
The patent application (U.S. Patent Application Serial No.14/561,091), which is owned by Mary’s Medicinals, was filed on Dec. 4, 2014 by inventor Nicole Smith. Mary’s Chief Scientist, Noel Palmer, Ph.D. is also listed as an inventor. Mary’s Medicinals has additional patent applications filed and pending for its other unique cannabis products.
About Mary’s Medicinals:
Mary’s Medicinals is a wellness company innovating at the intersection of engineering and horticulture. Mary’s is focused on transforming how people view and utilize cannabis, developing trusted products that isolate the benefits of cannabis and other vital plant extracts for optimum patient care. More information is available at: www.marysmedicinals.com
The statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficiency of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure or prevent any disease. All information presented here is not meant as a substitute for or alternative to information from health care practitioners. If you are taking any medication or are under treatment for any disease, please consult your health care professional about potential interactions or other possible complications before using these products. The Federal Food, Drug and Cosmetic Act requires this notice.
Supporting Resources:
Follow @Marysmedicinals on:
- Facebook: https://www.facebook.com/marymedicinalsofficial/
- Twitter: https://twitter.com/marysmedicinals
Press Contact:
Graham Sorkin
graham@marysmedicinals.com
720-262-8439
Original press release: http://www.prnewswire.com/news-releases/marys-medicinals-receives-notice-of-allowance-of-us-patent-for-transdermal-cannabinoid-formulations-300267427.html
